A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in …

K Nosek, W Leppert, H Nosek… - Drug Design …, 2017 - Taylor & Francis
Aim of the study To compare analgesia and adverse effects during oral morphine and
oxycodone and transdermal fentanyl and buprenorphine administration in cancer patients …

Comparison of the quality of life of cancer patients with pain treated with oral controlled-release morphine and oxycodone and transdermal buprenorphine and …

W Leppert, K Nosek - Current Pharmaceutical Design, 2019 - ingentaconnect.com
Aim: To compare the effects of oral morphine and oxycodone and transdermal fentanyl and
buprenorphine on quality of life (QoL) of cancer patients with severe pain. Patients and …

Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management

S Mercadante, G Porzio, P Ferrera, F Fulfaro… - European Journal of …, 2008 - Elsevier
PURPOSE: The aim of this study was to compare the analgesic and adverse effects, doses,
as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in …

Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain

TL Skaer - Journal of pain research, 2014 - Taylor & Francis
Opioids continue to be first-line pharmacotherapy for patients suffering from cancer pain.
Unfortunately, subtherapeutic dosage prescribing of pain medications remains common …

A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a …

A Roberto, MT Greco, L Legramandi, F Galli… - Journal of Pain …, 2017 - Taylor & Francis
Background Opioids are the most important pharmacological treatment for moderate-to-
severe cancer pain, but side effects limit their use. Transdermal fentanyl (TDF) and oral …

[HTML][HTML] Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain

P Poulain, W Denier, J Douma, K Hoerauf… - Journal of pain and …, 2008 - Elsevier
Strong opioids are recommended for treating severe cancer pain in the advanced stages of
the disease. Few data are available concerning the efficacy of buprenorphine in cancer …

Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review

D Tassinari, F Drudi, M Rosati… - Palliative medicine, 2011 - journals.sagepub.com
Background: To assess the role of transdermal opioids as a front-line approach to moderate
to severe cancer pain. Methods: A systematic review of the literature was performed by two …

[HTML][HTML] Equipotent doses to switch from high doses of opioids to transdermal buprenorphine

S Mercadante, A Casuccio, W Tirelli… - Supportive care in …, 2009 - Springer
Introduction The aim of this study was to evaluate the equianalgesic ratio of transdermal
buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive …

Transdermal opioids for cancer pain

E Cachia, SH Ahmedzai - … opinion in supportive and palliative care, 2011 - journals.lww.com
Transdermal opioids for cancer pain : Current Opinion in Supportive and Palliative Care
Transdermal opioids for cancer pain : Current Opinion in Supportive and Palliative Care Log in …

Pain management in palliative cancer patients: a prospective observational study on the use of high dosages of transdermal buprenorphine

PMJ Clement, B Beuselinck, PG Mertens… - Acta Clinica …, 2013 - Taylor & Francis
Introduction: Despite guidelines and recommendations, a large proportion of patients with
cancer still have inadequate pain control. Transdermal opioid administration can overcome …